This is the current revision of this page, as edited by Maxim Masiutin(talk | contribs) at 10:58, 12 January 2024(Added s2cid. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.). The present address (URL) is a permanent link to this version.
Revision as of 10:58, 12 January 2024 by Maxim Masiutin(talk | contribs)(Added s2cid. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.)
CGP-35348 was ineffective up to 100 μM to antagonize the inhibitory release of GABA elicited by baclofen, doing so selectively as a GABAB heteroreceptor antagonist.
[4] Moreover, CGP-35348 was about threefold less potent in antagonizing gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) than baclofen and SKF-97,541.[5]
^Carter LP, Chen W, Coop A, Koek W, France CP (May 2006). "Discriminative stimulus effects of GHB and GABA(B) agonists are differentially attenuated by CGP35348". European Journal of Pharmacology. 538 (1–3): 85–93. doi:10.1016/j.ejphar.2006.03.039. PMID16647701.
^Nasrallah FA, Griffin JL, Balcar VJ, Rae C (August 2007). "Understanding your inhibitions: modulation of brain cortical metabolism by GABA(B) receptors". Journal of Cerebral Blood Flow and Metabolism. 27 (8): 1510–20. doi:10.1038/sj.jcbfm.9600453. PMID17293844. S2CID16069846.